Title

A Clinical Trial of Zutectra in Patients Who Recently Received a Liver Transplant
An Open, Prospective, Single Arm Study Investigating Efficacy and Safety of Human Hepatitis B Immunoglobulin Zutectra in Liver Transplanted Patients - the ZEUS Study
  • Phase

    Phase 3
  • Study Type

    Interventional
  • Status

    Completed No Results Posted
  • Intervention/Treatment

    zutectra ...
  • Study Participants

    49
Patients who receive liver transplantation for hepatitis B virus (HBV) induced liver failure require longterm therapy to prevent HBV reinfection of the transplanted liver. The approved preventative treatment is a combination of antihepatitis B immunoglobulin (HBIg) and oral antiviral medication. In the first 6 months after liver transplantation, patients receive treatment with intravenous HBIg to maintain blood antihepatitis B (antiHBs)antibody concentrations above 100 IU/L, the level considered safe for preventing hepatitis B reinfection.

Zutectra is an HBIg preparation for subcutaneous injection that is approved in the EU for the 'prevention of HBV reinfection in HBV DNA negative patients ≥ 6 months after liver transplantation for hepatitis B induced liver failure'. The purpose of this study is to show that earlier subcutaneous HBIg treatment with Zutectra after liver transplantation can prevent hepatitis B reinfection.

Treatment with subcutaneous HBIg (Zutectra) at home is manageable for the majority of patients and is more convenient for patients compared to intravenous treatment that must take place in the hospital setting.

Fourty patients will take part in the study at approximately 19 centres in UK, France, Italy and Spain. Patients who are eligible for the study will receive treatment with Zutectra for 24 weeks.

During the study, the safety and effectiveness of Zutectra will be assessed by checking for symptoms of hepatitis B related infection, as well as monitoring blood levels of antiHBs antibodies and hepatitis B surface antigen (HBsAg).
Study Started
Dec 31
2012
Primary Completion
Sep 30
2014
Study Completion
Sep 30
2014
Last Update
Mar 25
2015
Estimate

Drug Zutectra

Subcutaneous injections of Zutectra up to 1,000 IU (2 ml) per week.

  • Other names: Human hepatitis B Immunoglobulin, HBIg

Zutectra Experimental

Subcutaneous injections of Zutectra up to 1,000 IU (2 ml) per week.

Criteria

Inclusion Criteria:

Written informed consent obtained prior to orthotopic liver transplantation (OLT) - not more than 3 months before OLT
Historical evidence within the last 4 weeks that HBV-DNA is undetectable at time point of signature of Informed Consent
Male and female patients (age 18-75 years)
Patients with the diagnosis of liver failure with hepatitis B infection
Patients undergoing liver transplantation or re-transplantation
HBsAg negative on day 7 or on day 14 after OLT
HBV-DNA undetectable at OLT
Serum HBs antibody concentration on day 7 or on day 14 after OLT ≥ 400 IU/l
Stable patient in a condition which in the opinion of the investigator would permit safe participation in the study
Willingness to fill out patient diary

Exclusion Criteria:

Re-transplantation due to viral recurrence
Positive HIV or HCV test at time of transplantation
HBV-DNA positive at OLT
Patients having received organs from HBsAg positive donors
Pregnancy or unreliable contraceptive measures or lactation period (females only)
Known intolerance to immunoglobulins or comparable substances (e.g. vaccination reaction)
Known intolerance to proteins of human origin
Participation in another interventional clinical trial within 90 days before entering the study or during the study and/or previous participation in this study (except screening failures)
Suspicion of drug and/or alcohol abuse
Inability or lacking motivation to participate in the study
Employee or direct relative of an employee of the CRO, the study site, or Biotest
No Results Posted